NCT00168753已完成4 期
An Open-Label Community-Based Study to Determine the Safety and Efficacy of an Extended Course of Alefacept, Following a Standard 12-Week Course of Amevive®, With Commonly Used Clinical Assessment Tools
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 114
- 试验地点
- 36
- 主要终点
- To evaluate the safety of treating subjects with up to 12 additional doses of alefacept 15 mg IM following a standard 12-week course of AMEVIVE.
研究概览
简要总结
To evaluate the safety of treating subjects with up to 12 additional doses of alefacept.
详细描述
Male and female subjects at least 18 years of age with moderate to severe plaque psoriasis treated with 12 weeks of alefacept 15 mg IM and who have not achieved the desired response.
Dosing Groups: Subjects will receive either 4, 8, or 12 doses of alefacept 15 mg IM weekly immediately (within 14 days) following a standard 12-dose course of AMEVIVE® 15 mg IM. Determination of number of doses will be based on physician qualitative assessment at weeks 4 and 8.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must give written informed consent.
- •Must have had moderate, moderately severe or severe chronic plaque psoriasis as determined by the investigator prior to initial treatment (baseline) with AMEVIVE.
- •Must be 18 years of age or older.
- •Must have completed a standard 12-week course of AMEVIVE and have received at least 10 doses.
- •Response to current AMEVIVE therapy must be less than a desired response as determined by the physician, and subject and some residual psoriasis must be present.
排除标准
- •Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or not willing to practice effective contraception during the study.
- •Nursing mothers, pregnant women, and women planning to become pregnant
- •Current enrollment in any investigational study in which the subject is receiving any type of drug, biologic, or non-drug therapy.
- •Treatment with another investigational drug, or approved therapy for investigational use, within 3 months of investigational drug administration.
- •Treatment with systemic retinoids, systemic steroids, methotrexate, cyclosporine, azathioprine, thioguanine, etanercept, efalizumab, infliximab, adalimumab or mycophenolate mofetil or other systemic immunosuppressant agents within 4 weeks of investigational drug administration.
- •Treatment with Ultraviolet B (UVB) phototherapy or Psoralen + Ultraviolet A (PUVA), within 4 weeks of investigational drug administration.
- •Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within the 3 months prior to the first dose of investigational drug.
- •History of >3 cutaneous squamous cell carcinomas or any systemic malignancy.
- •Skin lesions suspicious for malignancy.
- •Known HIV, viral hepatitis, or tuberculosis infection.
- •History of severe allergic or anaphylactic reactions.
- •ALT or AST greater than three times the upper limit of normal.
- •Significantly abnormal hematology (hemoglobin, hematocrit, platelets, white blood cells), as determined by the investigator.
- •CD4+ T lymphocyte count at screening visit less than 250 cells/mm
- •Known hypersensitivity to AMEVIVE or any of its components.
- •Subject's inability to comply with study requirements.
研究组 & 干预措施
1
Experimental
干预措施: Alefacept (Drug)
结局指标
主要结局
To evaluate the safety of treating subjects with up to 12 additional doses of alefacept 15 mg IM following a standard 12-week course of AMEVIVE.
时间窗: 16 weeks, 20 weeks or 24 weeks
次要结局
- The cumulative change in PQA score from screening visit to best PQA score at any time in the study,(End of study)
- The proportion of subjects who achieve moderate improvement, significant improvement or clear, as assessed by the PQA score, at any time during the study,(End of study)
- Association of subject assessment of efficacy with physician assessment of efficacy as measured by the SSA score and PQA score respectively.(End of study)
- The cumulative change in SSA score from screening visit to best SSA score at any time in the study,(End of study)
- Time to re-treatment for subjects who achieve moderate improvement, significant improvement or clear, as assessed by the PQA score, at any time during the study,(End of study)
- Association of the total number of doses received with the best efficacy reached, as assessed by PQA score, at any time during the study,(End of study)
- Association of the total number of doses received with the best efficacy reached, as assessed by SSA score, at any time during the study, and(End of study)
研究者
研究点 (36)
Loading locations...
相似试验
已完成
3 期
Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque PsoriasisPsoriasisNCT00692172Astellas Pharma Inc175
已完成
4 期
Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT00832585Rush University Medical Center5
已完成
3 期
Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) HeadachesMigraineNCT01035983Endo Pharmaceuticals550
已完成
3 期
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney DiseaseChronic Hepatitis CHepatitis C VirusCompensated CirrhosisSevere Renal ImpairmentEnd-stage Renal DiseaseNCT02207088AbbVie68
撤回
3 期
Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)Chronic Hepatitis C VirusNCT02806362AbbVie